STOCK TITAN

STANDARD BIOTOOLS INC - LAB STOCK NEWS

Welcome to our dedicated page for STANDARD BIOTOOLS news (Ticker: LAB), a resource for investors and traders seeking the latest updates and insights on STANDARD BIOTOOLS stock.

Overview

Standard BioTools Inc. (Nasdaq: LAB), previously known as Fluidigm Corporation, is a company specializing in the development, manufacturing, and commercialization of advanced biomedical research tools. The company focuses on delivering next-generation technologies that enable researchers to accelerate the discovery and development of new medicines through robust and repeatable insights in health and disease.

Core Technologies and Solutions

At the heart of Standard BioTools’ offerings are its proprietary mass cytometry and microfluidics platforms. These technologies empower biomedical scientists by providing high-throughput, automated, and precision-driven analytical solutions. The company's instruments and assays are designed to process small sample volumes with exceptional sensitivity, facilitating thousands of biochemical measurements in parallel. This capability is critical for applications in proteomics and genomics, where reproducible and precise data is essential for understanding complex biological systems.

Business Segments and Market Focus

The company is organized into key segments, notably the Proteomics and Genomics divisions. While its Proteomics segment remains a prominent revenue generator, the Genomics segment extends the utility of its technology to provide comprehensive insights into gene expression and molecular biology. Standard BioTools serves a diverse range of customers, including academic institutions, government laboratories, pharmaceutical and biotechnology companies, and clinical research organizations. This broad customer base reflects its commitment to supporting the most pressing needs in translational and clinical research.

Operational Excellence and Innovation

Standard BioTools is recognized for its emphasis on operational excellence and continuous innovation. The company leverages automation and streamlined workflows—such as advanced slide loaders and integrated software solutions—to reduce operational costs while enhancing throughput and data quality. These innovations not only simplify complex assay procedures but also ensure that researchers can obtain reliable, reproducible data efficiently.

Industry Impact and Competitive Landscape

In an increasingly competitive landscape, Standard BioTools differentiates itself through its comprehensive suite of standardized tools and its ability to execute high-content proteomics and spatial biology applications. Its technologies enable researchers to uncover detailed biomarker profiles with minimal sample requirements, which is particularly valuable in complex disease research. The company’s integrated customer solutions and emphasis on operational efficiency allow it to stand apart from competitors by providing a robust platform that addresses both academic and commercial research challenges.

Research Applications and Customer Benefits

The offerings from Standard BioTools facilitate a wide array of research applications such as oncology, immunology, and immunotherapy. By delivering tools that generate high-quality data, the company empowers customers to translate scientific discoveries into improved patient outcomes. Its platforms enable comprehensive protein and gene analysis, aiding in tasks from early-stage biomarker discovery to detailed mechanism-of-action studies in clinical trials. This positions Standard BioTools as a critical partner in the pursuit of innovative therapies and transformative breakthroughs in human health.

Commitment to Quality and Repeatability

Quality and repeatability are central to Standard BioTools’ mission. The company’s technologies are designed with precision and consistency in mind, supporting rigorous scientific inquiry and reducing the margin for error in high-stakes research environments. By adhering to the highest standards of data integrity, Standard BioTools builds trust within the scientific community and drives sustained value for its stakeholders.

Conclusion

Standard BioTools Inc. is a key player in the life sciences tools industry, offering innovative, high-throughput solutions that empower biomedical researchers worldwide. Its advanced platforms and steadfast commitment to quality provide a competitive edge in a dynamic market, supporting the global pursuit of improved health outcomes through faster and better medicine development.

Rhea-AI Summary
Standard BioTools Inc. (Nasdaq:LAB) announced that CEO Michael Egholm will give a presentation at the Jefferies London Healthcare Conference on November 15 at 11:00 a.m. GMT. The presentation will be webcast live and available on the company's Investor Relations page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
conferences
-
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq:LAB) will report Q3 2023 financial results on November 7, 2023, after the market close. A conference call and webcast will be held to discuss the results and operational progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.5%
Tags
-
Rhea-AI Summary
Lifshitz Law PLLC announces investigations of PFIS, KITT, and LAB
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.63%
Tags
none
Rhea-AI Summary
Standard BioTools and SomaLogic announce an all-stock merger, creating a leading provider of multi-omics tools for research with a pro-forma equity value of over $1 billion. The combined company expects to generate $80 million in annual cost synergies by 2026. Standard BioTools increases full year 2023 revenue guidance to $100 - $105 million, while SomaLogic reaffirms full year 2023 revenue guidance of $80 - $84 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.22%
Tags
-
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq:LAB) reported financial results for Q2 2023. Total revenue grew 47% in Q2 and 17% in the first half of 2023. Non-GAAP gross margin expanded by over 2,000 basis points in Q2 and over 1,000 basis points in the first half of 2023. Non-GAAP operating expenses declined by 25% in Q2 and by 26% in the first half of 2023. Non-GAAP adjusted EBITDA loss improved by over $17 million in Q2 and over $27 million in the first half of 2023. Cash, cash equivalents, and short-term investments on June 30, 2023, totaled $143 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.56%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
conferences
Rhea-AI Summary
Standard BioTools Inc. (LAB) will report Q2 2023 financial results on August 8, 2023, after market close. The company aims to accelerate breakthroughs in human health. The management will host a conference call and webcast to discuss the financial results and operational progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.31%
Tags
none

FAQ

What is the current stock price of STANDARD BIOTOOLS (LAB)?

The current stock price of STANDARD BIOTOOLS (LAB) is $1.07 as of April 4, 2025.

What is the market cap of STANDARD BIOTOOLS (LAB)?

The market cap of STANDARD BIOTOOLS (LAB) is approximately 390.4M.

What is the primary focus of Standard BioTools Inc.?

Standard BioTools Inc. focuses on developing and manufacturing advanced biomedical research tools, particularly in proteomics, mass cytometry, and microfluidics.

What technologies does Standard BioTools utilize?

The company utilizes proprietary mass cytometry and microfluidics technologies, which are integrated into high-throughput instruments and assays for detailed biochemical measurement.

How does Standard BioTools serve the research community?

It provides reliable, repeatable insights in both health and disease through its advanced platforms, serving academic, governmental, pharmaceutical, biotechnology, and clinical research organizations.

What are the main business segments of Standard BioTools?

The company primarily operates in the Proteomics and Genomics segments, with a strong emphasis on the Proteomics segment as a significant revenue driver.

How does the company differentiate itself from competitors?

Through its commitment to operational excellence, integrated automation solutions, and the ability to generate high-quality, reproducible data with minimal sample volumes.

What kind of research applications benefit from Standard BioTools' technologies?

Its technologies support a variety of research areas including oncology, immunology, immunotherapy, and other translational and clinical research applications.

Who are the key customers of Standard BioTools?

Key customers include academic institutions, government laboratories, pharmaceutical and biotechnology companies, and clinical research organizations worldwide.

How does Standard BioTools ensure quality and repeatability in its platforms?

The company emphasizes precision engineering, streamlined workflows, and quality control measures, ensuring that its platforms deliver consistent and reliable data over numerous applications.
STANDARD BIOTOOLS INC

Nasdaq:LAB

LAB Rankings

LAB Stock Data

390.36M
370.01M
1.86%
73.11%
3.81%
Medical Devices
Laboratory Analytical Instruments
Link
United States
SOUTH SAN FRANCISCO